87 related articles for article (PubMed ID: 17043751)
1. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ET(A) endothelin receptor antagonist, in spontaneoulsy hypertensive hamsters.
Rubinstein I
Cardiovasc Drugs Ther; 2006 Oct; 20(5):387-90. PubMed ID: 17043751
[TBL] [Abstract][Full Text] [Related]
2. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
[TBL] [Abstract][Full Text] [Related]
3. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
[TBL] [Abstract][Full Text] [Related]
4. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
Langleben D; Cacoub P
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
[TBL] [Abstract][Full Text] [Related]
5. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
Schiffrin EL; Turgeon A; Deng LY
Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
[TBL] [Abstract][Full Text] [Related]
7. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D; Brock T; Dixon R; Barst R;
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
[TBL] [Abstract][Full Text] [Related]
8. Sitaxsentan in the management of pulmonary arterial hypertension.
Benedict NJ
Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175
[TBL] [Abstract][Full Text] [Related]
9. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
Barst RJ
Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810
[TBL] [Abstract][Full Text] [Related]
10. Selective endothelin-A receptor inhibition after cardiac surgery: a safety and feasibility study.
Ikonomidis JS; Hilton EJ; Payne K; Harrell A; Finklea L; Clark L; Reeves S; Stroud RE; Leonardi A; Crawford FA; Spinale FG
Ann Thorac Surg; 2007 Jun; 83(6):2153-60; discussion 2161. PubMed ID: 17532415
[TBL] [Abstract][Full Text] [Related]
11. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
Rondelet B; Kerbaul F; Vivian GF; Hubloue I; Huez S; Fesler P; Remmelink M; Brimiouille S; Salmon I; Naeije R
Pediatr Res; 2007 Mar; 61(3):284-8. PubMed ID: 17314684
[TBL] [Abstract][Full Text] [Related]
12. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
[TBL] [Abstract][Full Text] [Related]
13. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats.
Bolterman RJ; Manriquez MC; Ortiz Ruiz MC; Juncos LA; Romero JC
Hypertension; 2005 Oct; 46(4):943-7. PubMed ID: 16087785
[TBL] [Abstract][Full Text] [Related]
14. Impaired response of the denervated kidney to endothelin receptor blockade in normotensive and spontaneously hypertensive rats.
Girchev R; Bäcker A; Markova P; Kramer HJ
Kidney Int; 2004 Mar; 65(3):982-9. PubMed ID: 14871418
[TBL] [Abstract][Full Text] [Related]
15. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
[TBL] [Abstract][Full Text] [Related]
16. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
Horn EM; Widlitz AC; Barst RJ
Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
[TBL] [Abstract][Full Text] [Related]
17. Sitaxsentan for treatment of pulmonary hypertension.
Wittbrodt ET; Abubakar A
Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment.
Dhaun N; Melville V; Kramer W; Stavros F; Coyne T; Swan S; Goddard J; Webb DJ
Br J Clin Pharmacol; 2007 Dec; 64(6):733-7. PubMed ID: 17635499
[TBL] [Abstract][Full Text] [Related]
19. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
Rubinstein I; Ikezaki H; Onyüksel H
Int J Pharm; 2006 Jun; 316(1-2):144-7. PubMed ID: 16580160
[TBL] [Abstract][Full Text] [Related]
20. Selective and mixed endothelin receptor antagonism in cardiovascular disease.
Dhaun N; Pollock DM; Goddard J; Webb DJ
Trends Pharmacol Sci; 2007 Nov; 28(11):573-9. PubMed ID: 17950470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
